Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...
BACKGROUND: Hypertension induces structural and functional damage in multiple organs. Evidence of subclinical damage ...
“Bruin CLL-322 was an ambitious trial, building on an effective regimen, and these results outperformed our expectations,” Jacob Van Naarden, president of Lilly Oncology, said in an April 13 release. ...
Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...
Constitutive activation of the B-cell receptor (BCR) signaling pathway is a hallmark of chronic lymphocytic leukemia (CLL), driving the malignant cell survival, proliferation, and interaction with the ...
Error-corrected sequencing of non–B-cell fractions in CLL12/CLL14 detected CH in ~58% of CLL, with 35% meeting CHIP criteria. Cytotoxic regimens, especially chlorambucil-based therapy, were linked to ...
Please provide your email address to receive an email when new articles are posted on . The combination is the first all-oral, fixed duration treatment for patients with CLL and or small lymphocytic ...
In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...
It’s hard to ignore the seismic shifts brought about by algorithm-driven content. Every time you scroll through your social media feed or check your favorite news app, algorithms are diligently at ...
In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted ...
Learn how recommendation algorithms, streaming recommendations, and social media algorithms use content recommendation systems to deliver personalized recommendations. Pixabay, TungArt7 From movie ...
Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results